PURPOSE: A splice variant of the androgen receptor, AR-V7, confers resistance to AR-targeted therapies (ATTs) but not taxane chemotherapies in patients with metastatic castration-resistant prostate cancer. Since August 2015, a clinical-grade assay to detect AR-V7 messenger RNA expression in circulating tumors cells (CTCs) has been available to providers through a Clinical Laboratory Improvement Amendments-certified laboratory at Johns Hopkins University. METHODS: We contacted ordering providers of the first 150 consecutive tests by using a questionnaire-based survey to determine how the results of AR-V7 testing were used to influence clinical practice. RESULTS: In all, 142 (95%) of 150 questionnaires were completed by 38 providers from 29 sites across the United States and Canada. AR-V7 test results were reported either as CTC- (28%), CTC+/AR-V7- (30%), or CTC+/AR-V7+ (42%). Prevalence of AR-V7 detection increased with prior exposure to ATTs (abiraterone and enzalutamide naïve, 22%; after abiraterone or enzalutamide, 35%; after abiraterone and enzalutamide, 43%). Overall, management was affected by AR-V7 testing in 53% of the patients and even more often with CTC+/AR-V7+ results. AR-V7+ patients were commonly switched from ATT to taxane chemotherapy (43%) or were offered a clinical trial (43%); management remained unchanged in only 14% of these patients. Overall, patients who had a change in management on the basis of AR-V7 testing were significantly more likely to achieve a physician-reported 50% decline in prostate-specific antigen response on next-line therapy than those who did not change treatment (54% v 31%; P = .015). CONCLUSION: Providers used AR-V7 testing to influence clinical decision making more often than not. Physicians reported thatmenwithAR-V7+results had the most treatment changes, and such men were preferentially managed with taxane therapy or offered a clinical trial, which may have improved outcomes.
PURPOSE: A splice variant of the androgen receptor, AR-V7, confers resistance to AR-targeted therapies (ATTs) but not taxane chemotherapies in patients with metastatic castration-resistant prostate cancer. Since August 2015, a clinical-grade assay to detect AR-V7 messenger RNA expression in circulating tumors cells (CTCs) has been available to providers through a Clinical Laboratory Improvement Amendments-certified laboratory at Johns Hopkins University. METHODS: We contacted ordering providers of the first 150 consecutive tests by using a questionnaire-based survey to determine how the results of AR-V7 testing were used to influence clinical practice. RESULTS: In all, 142 (95%) of 150 questionnaires were completed by 38 providers from 29 sites across the United States and Canada. AR-V7 test results were reported either as CTC- (28%), CTC+/AR-V7- (30%), or CTC+/AR-V7+ (42%). Prevalence of AR-V7 detection increased with prior exposure to ATTs (abiraterone and enzalutamide naïve, 22%; after abiraterone or enzalutamide, 35%; after abiraterone and enzalutamide, 43%). Overall, management was affected by AR-V7 testing in 53% of the patients and even more often with CTC+/AR-V7+ results. AR-V7+ patients were commonly switched from ATT to taxane chemotherapy (43%) or were offered a clinical trial (43%); management remained unchanged in only 14% of these patients. Overall, patients who had a change in management on the basis of AR-V7 testing were significantly more likely to achieve a physician-reported 50% decline in prostate-specific antigen response on next-line therapy than those who did not change treatment (54% v 31%; P = .015). CONCLUSION: Providers used AR-V7 testing to influence clinical decision making more often than not. Physicians reported thatmenwithAR-V7+results had the most treatment changes, and such men were preferentially managed with taxane therapy or offered a clinical trial, which may have improved outcomes.
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis Journal: Ann Oncol Date: 2015-06-27 Impact factor: 32.976
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Yezi Zhu; John L Silberstein; Maritza N Taylor; Benjamin L Maughan; Samuel R Denmeade; Kenneth J Pienta; Channing J Paller; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: J Clin Oncol Date: 2017-04-06 Impact factor: 44.544
Authors: Parvez M Lokhandwala; Stacy L Riel; Lisa Haley; Changxue Lu; Yan Chen; John Silberstein; Yezi Zhu; Gang Zheng; Ming-Tseh Lin; Christopher D Gocke; Alan W Partin; Emmanuel S Antonarakis; Jun Luo; James R Eshleman Journal: J Mol Diagn Date: 2016-12-01 Impact factor: 5.568
Authors: Andres Jan Schrader; Martin Boegemann; Carsten-H Ohlmann; Thomas J Schnoeller; Laura-Maria Krabbe; Turkan Hajili; Florian Jentzmik; Michael Stoeckle; Mark Schrader; Edwin Herrmann; Marcus V Cronauer Journal: Eur Urol Date: 2013-07-02 Impact factor: 20.096
Authors: Wendy Onstenk; Anieta M Sieuwerts; Jaco Kraan; Mai Van; Annemieke J M Nieuweboer; Ron H J Mathijssen; Paul Hamberg; Hielke J Meulenbeld; Bram De Laere; Luc Y Dirix; Robert J van Soest; Martijn P Lolkema; John W M Martens; Wytske M van Weerden; Guido W Jenster; John A Foekens; Ronald de Wit; Stefan Sleijfer Journal: Eur Urol Date: 2015-07-15 Impact factor: 20.096
Authors: Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore Journal: JAMA Oncol Date: 2016-11-01 Impact factor: 31.777
Authors: Eugene Shenderov; Karim Boudadi; Wei Fu; Hao Wang; Rana Sullivan; Alice Jordan; Donna Dowling; Rana Harb; Joseph Schonhoft; Adam Jendrisak; Michael A Carducci; Mario A Eisenberger; James R Eshleman; Jun Luo; Charles G Drake; Drew M Pardoll; Emmanuel S Antonarakis Journal: Prostate Date: 2021-02-26 Impact factor: 4.104
Authors: Keith T Schmidt; Cindy H Chau; Jonathan D Strope; Alwin D R Huitema; Tristan M Sissung; Douglas K Price; William D Figg Journal: Mol Cancer Ther Date: 2021-02-25 Impact factor: 6.009
Authors: Mark C Markowski; Hao Wang; Rana Sullivan; Irina Rifkind; Victoria Sinibaldi; Michael T Schweizer; Benjamin A Teply; Nduku Ngomba; Wei Fu; Michael A Carducci; Channing J Paller; Catherine H Marshall; Mario A Eisenberger; Jun Luo; Emmanuel S Antonarakis; Samuel R Denmeade Journal: Eur Urol Date: 2020-07-02 Impact factor: 20.096
Authors: Edmond M Kwan; Chao Dai; Heidi Fettke; Christine Hauser; Maria M Docanto; Patricia Bukczynska; Nicole Ng; Siavash Foroughi; Lisa-Jane K Graham; Kate Mahon; Winston Tan; Xiaohong Wang; Zhixin Zhao; Tiantian Zheng; Kemin Zhou; Jianjun Yu; Pan Du; Lisa G Horvath; Shidong Jia; Manish Kohli; Arun A Azad Journal: JCO Precis Oncol Date: 2021-04-06
Authors: Ada Gjyrezi; Giuseppe Galletti; Jiaren Zhang; Daniel Worroll; Michael Sigouros; Seaho Kim; Victoria Cooley; Karla V Ballman; Allyson J Ocean; Manish A Shah; Joseph M Scandura; Andrea Sboner; David M Nanus; Himisha Beltran; Scott Tagawa; Paraskevi Giannakakou Journal: Commun Biol Date: 2021-06-24